Response criteria for rheumatoid arthritis in clinical practice:: how useful are they?

被引:28
作者
Gülfe, A [1 ]
Geborek, P [1 ]
Saxne, T [1 ]
机构
[1] Univ Lund Hosp, Dept Rheumatol, SE-22185 Lund, Sweden
关键词
D O I
10.1136/ard.2004.027649
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Objective: To compare the performance of the American College of Rheumatology (ACR), European League Against Rheumatism (EULAR), and simple disease activity index (SDAI) response criteria for rheumatoid arthritis at the individual level in an observational cohort. Methods: 184 outpatients were followed using a structured protocol. For each patient, the responses according to ACR 20% and 50%, EULAR moderate and good, and SDAI minor and major responses were calculated. For comparison, improvements in health assessment questionnaire (HAQ) score of 0.22 and 0.5 were calculated. The numbers of individuals fulfilling the criteria at each level were compared, and the numbers fulfilling any two sets of response criteria calculated. The EULAR "moderate'' and "good'' responses were grouped together as "overall,'' and SDAI "minor'' and "major'' were merged into SDAI "overall''. Results: All 94 ACR 20 responders were found in the EULAR and SDAI "overall'' response groups, and 118 of 124 SDAI "overall'' responders were found in the EULAR "overall'' group. In contrast, of 53 ACR 50 responders, only 34 were found in the EULAR "good'' or SDAI "major'' group. Among the 56 patients in the EULAR "good'' response group, only 26 met the SDAI "major'' response. Improvement in HAQ score performed similarly to the other response criteria sets at the group levels. Conclusions: For individual patients, agreement is good at the level of ACR 20 response, when EULAR overall, SDAI overall, or HAQ 0.22 criteria are applied. Agreement between ACR 50, EULAR good, SDAI major, and HAQ 0.5 response is poor. This should be considered when response criteria are used for clinical decisions.
引用
收藏
页码:1186 / 1189
页数:4
相关论文
共 16 条
[1]
THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[2]
ASSESSING DISABILITY IN PATIENTS WITH RHEUMATOID-ARTHRITIS - USE OF A SWEDISH VERSION OF THE STANFORD HEALTH ASSESSMENT QUESTIONNAIRE [J].
EKDAHL, C ;
EBERHARDT, K ;
ANDERSSON, SI ;
SVENSSON, B .
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1988, 17 (04) :263-271
[3]
AMERICAN-COLLEGE-OF-RHEUMATOLOGY PRELIMINARY DEFINITION OF IMPROVEMENT IN RHEUMATOID-ARTHRITIS [J].
FELSON, DT ;
ANDERSON, JJ ;
BOERS, M ;
BOMBARDIER, C ;
FURST, D ;
GOLDSMITH, C ;
KATZ, LM ;
LIGHTFOOT, R ;
PAULUS, H ;
STRAND, V ;
TUGWELL, P ;
WEINBLATT, M ;
WILLIAMS, HJ ;
WOLFE, F ;
KIESZAK, S .
ARTHRITIS AND RHEUMATISM, 1995, 38 (06) :727-735
[4]
FERRAZ MB, 1990, J RHEUMATOL, V17, P1022
[5]
MEASUREMENT OF PATIENT OUTCOME IN ARTHRITIS [J].
FRIES, JF ;
SPITZ, P ;
KRAINES, RG ;
HOLMAN, HR .
ARTHRITIS AND RHEUMATISM, 1980, 23 (02) :137-145
[6]
Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis [J].
Geborek, P ;
Saxne, T .
RHEUMATOLOGY, 2000, 39 (10) :1159-1161
[7]
Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden [J].
Geborek, P ;
Crnkic, M ;
Petersson, IF ;
Saxne, T .
ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (09) :793-798
[8]
The cost-effectiveness of infliximab (Remicade®) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study [J].
Kobelt, G ;
Jönsson, L ;
Young, A ;
Eberhardt, K .
RHEUMATOLOGY, 2003, 42 (02) :326-335
[9]
An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the disease activity score (DAS) in a rheumatoid arthritis clinical trial [J].
Pincus, T ;
Strand, V ;
Koch, G ;
Amara, I ;
Crawford, B ;
Wolfe, F ;
Cohen, S ;
Felson, D .
ARTHRITIS AND RHEUMATISM, 2003, 48 (03) :625-630
[10]
MODIFIED DISEASE-ACTIVITY SCORES THAT INCLUDE 28-JOINT COUNTS - DEVELOPMENT AND VALIDATION IN A PROSPECTIVE LONGITUDINAL-STUDY OF PATIENTS WITH RHEUMATOID-ARTHRITIS [J].
PREVOO, MLL ;
VANTHOF, MA ;
KUPER, HH ;
VANLEEUWEN, MA ;
VANDEPUTTE, LBA ;
VANRIEL, PLCM .
ARTHRITIS AND RHEUMATISM, 1995, 38 (01) :44-48